Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NVE CORP /NEW/nvec · Entity 5507 | Director | August 06, 2020 | August 10, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NVE CORP /NEW/
Report date August 06, 2020 · Filed August 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $57.24 · Expires 2030-08-06 | Direct | 7,000 |
Reported balance
After 2020-08-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-08-06 · Grant · Acquired 1,000 · Balance 7,000 F1: Option granted automatically on Mr. Maharaj's reelection to NVE's Board of Directors |
Filing footnotes · ownership attribution and instrument terms
F1: Option granted automatically on Mr. Maharaj's reelection to NVE's Board of Directors
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SURMODICS INC
Report date November 19, 2025 · Filed November 19, 2025
Section 16 reporting ended · disclosed 2025-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-11-19 transaction · row 1
1 source rowRow 1 · 2025-11-19 · Disposition to issuer · Disposed 192,056 · Balance 0 F1: Pursuant to that certain Merger Agreement, dated as of May 28, 2024, by and among the Surmodics, Inc. (the "Issuer"), BCE Parent, LLC, ("Parent"), and BCE Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of the Issuer's common stock, par value $0.05 per share ("Common Stock"), that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive $43.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). All outstanding restricted stock units ("RSUs") held by the reporting person vested immediately prior to the Effective Time and the reporting person is entitled to receive the Merger Consideration for such vested RSUs. F2: As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Common Stock. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.63 · Expires 2025-11-27 | Direct | 0 |
Reported balance
After 2025-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-19 · Disposition to issuer · Disposed 45,073 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, this unexercised stock option ("Option") was cancelled and automatically converted into the right to receive an amount in cash (without interest) equal to the product of (a) the aggregate number of shares of Common Stock subject to the Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over such Option's applicable per share exercise price, subject to any required tax withholdings. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.00 · Expires 2026-11-26 | Direct | 0 |
Reported balance
After 2025-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-11-19 · Disposition to issuer · Disposed 62,674 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, this unexercised stock option ("Option") was cancelled and automatically converted into the right to receive an amount in cash (without interest) equal to the product of (a) the aggregate number of shares of Common Stock subject to the Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over such Option's applicable per share exercise price, subject to any required tax withholdings. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.93 · Expires 2028-11-30 | Direct | 0 |
Reported balance
After 2025-11-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-11-19 · Disposition to issuer · Disposed 73,349 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, this unexercised stock option ("Option") was cancelled and automatically converted into the right to receive an amount in cash (without interest) equal to the product of (a) the aggregate number of shares of Common Stock subject to the Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over such Option's applicable per share exercise price, subject to any required tax withholdings. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.13 · Expires 2029-11-30 | Direct | 0 |
Reported balance
After 2025-11-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-11-19 · Disposition to issuer · Disposed 84,669 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, this unexercised stock option ("Option") was cancelled and automatically converted into the right to receive an amount in cash (without interest) equal to the product of (a) the aggregate number of shares of Common Stock subject to the Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over such Option's applicable per share exercise price, subject to any required tax withholdings. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.64 · Expires 2030-12-04 | Direct | 0 |
Reported balance
After 2025-11-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-11-19 · Disposition to issuer · Disposed 89,127 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, this unexercised stock option ("Option") was cancelled and automatically converted into the right to receive an amount in cash (without interest) equal to the product of (a) the aggregate number of shares of Common Stock subject to the Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over such Option's applicable per share exercise price, subject to any required tax withholdings. |
| Employee Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.44 · Expires 2027-11-30 | Direct | 0 |
Reported balance
After 2025-11-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-11-19 · Disposition to issuer · Disposed 74,515 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, this unexercised stock option ("Option") was cancelled and automatically converted into the right to receive an amount in cash (without interest) equal to the product of (a) the aggregate number of shares of Common Stock subject to the Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over such Option's applicable per share exercise price, subject to any required tax withholdings. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Merger Agreement, dated as of May 28, 2024, by and among the Surmodics, Inc. (the "Issuer"), BCE Parent, LLC, ("Parent"), and BCE Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of the Issuer's common stock, par value $0.05 per share ("Common Stock"), that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive $43.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). All outstanding restricted stock units ("RSUs") held by the reporting person vested immediately prior to the Effective Time and the reporting person is entitled to receive the Merger Consideration for such vested RSUs.
F2: As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Common Stock.
F3: Pursuant to the Merger Agreement, at the Effective Time, this unexercised stock option ("Option") was cancelled and automatically converted into the right to receive an amount in cash (without interest) equal to the product of (a) the aggregate number of shares of Common Stock subject to the Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over such Option's applicable per share exercise price, subject to any required tax withholdings.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 27, 2020 Filed Nov 30, 2020 19:19 UTC | SURMODICS INC SRDX · Entity 72915 | Tax withholdingCommon Stock | 1,477 | $38.36 | $56,657.72 |
DisclosureSEC source: 0001209191-20-060803 · doc4.xml · nonDerivative · entry 2 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,750 Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 19:19 UTC | SURMODICS INC SRDX · Entity 72915 | Tax withholdingCommon Stock | 2,172 | $38.93 | $84,555.96 |
DisclosureSEC source: 0001209191-20-060803 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,227 Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 17:06 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 3,000 | $45.07 | $135,206.40 |
DisclosureSEC source: 0001209191-20-049456 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,399 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2020. F2 · price: Reflects the weighted average price of 3,000 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on September 1, 2020 with sale prices ranging from $44.58 to $45.355 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 257 shares acquired through the Employee Stock Purchase Plan for the phase ending August 31, 2020. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 10:26 UTC | NVE CORP /NEW/ nvec · Entity 5507 | GrantNon-Qualified Stock Option · Derivative | 1,000 | $0.00 Strike: $57.24 | $0.00 |
DisclosureSEC source: 0000724910-20-000036 · primary_doc.xml · derivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 1,000 shares Expires 2030-08-06 F1 · shares: Option granted automatically on Mr. Maharaj's reelection to NVE's Board of Directors Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 16:28 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 3,000 | $47.44 | $142,333.80 |
DisclosureSEC source: 0001209191-20-045109 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,142 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2020. F2 · price: Reflects the weighted average price of 3,000 shares of common stock of Surmodics, Inc. sold by the reporting person in multiple transactions on August 3, 2020 with sale prices ranging from $47.015 to $47.98 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 18:10 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 2,000 | $43.02 | $86,036.60 |
DisclosureSEC source: 0001179110-20-008058 · edgar.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,142 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2020. F2 · price: Reflects the weighted average price of 2,000 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on July 1, 2020 with sale prices ranging from $42.62 to $43.27 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 257 shares acquired through the Employee Stock Purchase Plan for the phase ending 02/28/20. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:32 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 702 | $41.08 | $28,841.04 |
DisclosureSEC source: 0001209191-20-002178 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,885 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2019. F2 · price: Reflects the weighted average price of 702 shares of common stock of Surmodics, Inc. sold by the reporting person in multiple transactions on January 2, 2020 with sale prices ranging from $40.77 to $41.59 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 16:34 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 730 | $40.74 | $29,742.90 |
DisclosureSEC source: 0001209191-19-059071 · doc4.xml · nonDerivative · entry 2 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,587 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2019. F3 · price: Reflects the weighted average price of 730 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on December 2, 2019 with sale prices ranging from $40.725 to $40.88 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 16:34 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 4,270 | $40.33 | $172,210.38 |
DisclosureSEC source: 0001209191-19-059071 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,317 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2019. F2 · price: Reflects the weighted average price of 4,270 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on December 2, 2019 with sale prices ranging from $39.725 to $40.67 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 30, 2019 Filed Dec 2, 2019 16:08 UTC | SURMODICS INC SRDX · Entity 72915 | Tax withholdingCommon Stock | 1,079 | $41.04 | $44,282.16 |
DisclosureSEC source: 0001209191-19-058510 · doc4.xml · nonDerivative · entry 3 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,587 Read SEC document |
| November 28, 2019 Filed Dec 2, 2019 16:08 UTC | SURMODICS INC SRDX · Entity 72915 | Tax withholdingCommon Stock | 1,969 | $40.89 | $80,512.41 |
DisclosureSEC source: 0001209191-19-058510 · doc4.xml · nonDerivative · entry 2 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,666 Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 16:08 UTC | SURMODICS INC SRDX · Entity 72915 | Tax withholdingCommon Stock | 1,477 | $40.89 | $60,394.53 |
DisclosureSEC source: 0001209191-19-058510 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,635 Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 15:26 UTC | SURMODICS INC SRDX · Entity 72915 | GrantEmployee Stock Option (right to buy) · Derivative | 62,674 | $0.00 Strike: $42.00 | $0.00 |
DisclosureSEC source: 0001209191-19-058304 · doc4.xml · derivative · entry 4 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,674 Underlying: Common Stock · 62,674 shares Expires 2026-11-25 F3 · derivative.exercise_date: The award vests in four equal installments on each of the first four anniversaries of the November 25, 2019 grant date. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 15:26 UTC | SURMODICS INC SRDX · Entity 72915 | GrantCommon Stock | 14,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-058304 · doc4.xml · nonDerivative · entry 3 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,112 Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 15:26 UTC | SURMODICS INC SRDX · Entity 72915 | Tax withholdingCommon Stock | 9,367 | $42.00 | $393,414.00 |
DisclosureSEC source: 0001209191-19-058304 · doc4.xml · nonDerivative · entry 2 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,827 F2 · shares: Shares withheld to satisfy taxes incident to vesting of performance share award. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 15:26 UTC | SURMODICS INC SRDX · Entity 72915 | GrantCommon Stock | 20,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-058304 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,194 F1 · shares: Performance shares awarded under long-term incentive plan based on performance during three-year period ended September 30, 2019. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 17:11 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 500 | $41.29 | $20,644.00 |
DisclosureSEC source: 0001209191-19-055278 · doc4.xml · nonDerivative · entry 2 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,653 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2019. F3 · price: Reflects the weighted average price of 500 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on November 1, 2019 with sale prices ranging from $40.96 to $41.77 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 17:11 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 4,500 | $40.52 | $182,318.40 |
DisclosureSEC source: 0001209191-19-055278 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,153 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2019. F2 · price: Reflects the weighted average price of 4,500 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on November 1, 2019 with sale prices ranging from $39.95 to $40.94 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 16:16 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 300 | $46.14 | $13,842.51 |
DisclosureSEC source: 0001209191-19-052142 · doc4.xml · nonDerivative · entry 2 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,653 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2019. F3 · price: Reflects the weighted average price of 300 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on October 1, 2019 with sale prices ranging from $46.06 to $46.305 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 16:16 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 4,700 | $45.46 | $213,654.95 |
DisclosureSEC source: 0001209191-19-052142 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,953 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2019. F2 · price: Reflects the weighted average price of 4,700 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on October 1, 2019 with sale prices ranging from $45.01 to $45.945 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:11 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 5,000 | $45.95 | $229,764.50 |
DisclosureSEC source: 0001209191-19-048488 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,653 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2019. F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on September 3, 2019 with sale prices ranging from $45.61 to $46.60 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 448 shares acquired through the Employee Stock Purchase Plan for the phase ending 8/30/19. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 20:32 UTC | NVE CORP /NEW/ nvec · Entity 5507 | GrantNon-Qualified Stock Option · Derivative | 1,000 | $0.00 Strike: $67.65 | $0.00 |
DisclosureSEC source: 0000724910-19-000033 · primary_doc.xml · derivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 1,000 shares Expires 2029-08-01 F1 · shares: Option granted automatically on Mr. Maharaj's reelection to NVE's Board of Directors Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 16:12 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 2,770 | $46.78 | $129,585.03 |
DisclosureSEC source: 0001209191-19-044510 · doc4.xml · nonDerivative · entry 2 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,205 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2019. F3 · price: Reflects the weighted average price of 2,770 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on August 1, 2019 with sale prices ranging from $46.68 to $47.31 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 16:12 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 2,230 | $46.15 | $102,913.39 |
DisclosureSEC source: 0001209191-19-044510 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,975 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2019. F2 · price: Reflects the weighted average price of 2,230 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on August 1, 2019 with sale prices ranging from $45.62 to $46.58 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 16:17 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 3,030 | $42.97 | $130,210.61 |
DisclosureSEC source: 0001209191-19-041074 · doc4.xml · nonDerivative · entry 2 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,205 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2019. F3 · price: Reflects the weighted average price of 3,030 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on July 1, 2019 with sale prices ranging from $42.71 to $43.34 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 16:17 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 1,970 | $42.18 | $83,086.72 |
DisclosureSEC source: 0001209191-19-041074 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,235 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2019. F2 · price: Reflects the weighted average price of 1,970 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on July 1, 2019 with sale prices ranging from $41.715 to $42.705 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:46 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 5,000 | $40.95 | $204,739.50 |
DisclosureSEC source: 0001209191-19-034770 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,205 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2019. F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on June 3, 2019 with sale prices ranging from $40.07 to $40.845 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2019 Filed May 3, 2019 16:16 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 5,000 | $42.68 | $213,390.00 |
DisclosureSEC source: 0001209191-19-027340 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,205 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2019. F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on May 1, 2019 with sale prices ranging from $42.35 to $43.255 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 15:56 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 5,000 | $42.90 | $214,498.00 |
DisclosureSEC source: 0001209191-19-023059 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,205 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2019. F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on April 1, 2019 with sale prices ranging from $42.62 to $43.34 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 171 shares acquired through the Employee Stock Purchase Plan for the phase ending 2/28/19. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 17:30 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 100 | $56.36 | $5,636.00 |
DisclosureSEC source: 0001209191-19-007428 · doc4.xml · nonDerivative · entry 8 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,034 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2018. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 17:30 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 300 | $55.53 | $16,659.00 |
DisclosureSEC source: 0001209191-19-007428 · doc4.xml · nonDerivative · entry 7 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,134 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2018. F8 · price: Reflects the weighted average price of 300 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on February 1, 2019 with sale prices ranging from $54.885 to $55.865 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 17:30 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 840 | $54.05 | $45,401.16 |
DisclosureSEC source: 0001209191-19-007428 · doc4.xml · nonDerivative · entry 6 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,434 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2018. F7 · price: Reflects the weighted average price of 840 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on February 1, 2019 with sale prices ranging from $53.805 to $54.33 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 17:30 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 925 | $53.05 | $49,071.44 |
DisclosureSEC source: 0001209191-19-007428 · doc4.xml · nonDerivative · entry 5 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,274 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2018. F6 · price: Reflects the weighted average price of 925 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on February 1, 2019 with sale prices ranging from $52.75 to $53.675 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 17:30 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 668 | $51.87 | $34,647.89 |
DisclosureSEC source: 0001209191-19-007428 · doc4.xml · nonDerivative · entry 4 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,199 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2018. F5 · price: Reflects the weighted average price of 668 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on February 1, 2019 with sale prices ranging from $51.561 to $52.20 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 16:50 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 100 | $46.83 | $4,683.00 |
DisclosureSEC source: 0001209191-19-002038 · doc4.xml · nonDerivative · entry 2 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,867 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2018. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 16:50 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 4,900 | $46.20 | $226,402.05 |
DisclosureSEC source: 0001209191-19-002038 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,967 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2018. F2 · price: Reflects the weighted average price of 4,900 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on January 2, 2019 with sale prices ranging from $45.76 to $46.67 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 16:20 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 896 | $60.38 | $54,099.23 |
DisclosureSEC source: 0001209191-18-060854 · doc4.xml · nonDerivative · entry 4 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,867 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2018. F4 · price: Reflects the weighted average price of 896 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on December 3, 2018 with sale prices ranging from $60.24 to $60.68 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 16:20 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 1,557 | $59.57 | $92,754.38 |
DisclosureSEC source: 0001209191-18-060854 · doc4.xml · nonDerivative · entry 3 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,763 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2018. F3 · price: Reflects the weighted average price of 1,557 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on December 3, 2018 with sale prices ranging from $59.205 to $60.16 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 16:20 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 2,547 | $58.85 | $149,891.97 |
DisclosureSEC source: 0001209191-18-060854 · doc4.xml · nonDerivative · entry 2 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,320 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2018. F2 · price: Reflects the weighted average price of 2,547 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on December 3, 2018 with sale prices ranging from $58.21 to $59.17 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 16:20 UTC | SURMODICS INC SRDX · Entity 72915 | Tax withholdingCommon Stock | 1,079 | $60.59 | $65,376.61 |
DisclosureSEC source: 0001209191-18-060854 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,867 Read SEC document |
| November 28, 2018 Filed Nov 29, 2018 16:09 UTC | SURMODICS INC SRDX · Entity 72915 | Tax withholdingCommon Stock | 1,969 | $60.06 | $118,258.14 |
DisclosureSEC source: 0001209191-18-060218 · doc4.xml · nonDerivative · entry 4 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,946 Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 16:09 UTC | SURMODICS INC SRDX · Entity 72915 | GrantEmployee Stock Option (right to buy) · Derivative | 45,073 | $0.00 Strike: $56.63 | $0.00 |
DisclosureSEC source: 0001209191-18-060218 · doc4.xml · derivative · entry 5 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,073 Underlying: Common Stock · 45,073 shares Expires 2025-11-27 F3 · derivative.exercise_date: The award vests in four equal installments on each of the first four anniversaries of the November 27, 2018 grant date. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 16:09 UTC | SURMODICS INC SRDX · Entity 72915 | Tax withholdingCommon Stock | 10,834 | $56.63 | $613,529.42 |
DisclosureSEC source: 0001209191-18-060218 · doc4.xml · nonDerivative · entry 3 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,915 F2 · shares: Shares withheld to satisfy taxes incident to vesting of performance share award. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 16:09 UTC | SURMODICS INC SRDX · Entity 72915 | GrantCommon Stock | 23,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-060218 · doc4.xml · nonDerivative · entry 2 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,749 F1 · shares: Shares issued in connection with the vesting of a performance share award under long-term incentive plan based on performance during three-year period ended September 30, 2018. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 16:09 UTC | SURMODICS INC SRDX · Entity 72915 | GrantCommon Stock | 9,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-060218 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,991 Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 16:38 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 807 | $62.64 | $50,552.66 |
DisclosureSEC source: 0001209191-18-057190 · doc4.xml · nonDerivative · entry 2 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,279 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2018. F3 · price: Reflects the weighted average price of 807 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on November 1, 2018 with sale prices ranging from $62.51 to $63.085 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 16:38 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 4,193 | $62.13 | $260,490.54 |
DisclosureSEC source: 0001209191-18-057190 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,086 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2018. F2 · price: Reflects the weighted average price of 4,193 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on November 1, 2018 with sale prices ranging from $61.50 to $62.43 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2018 Filed Feb 5, 2019 17:30 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 700 | $74.10 | $51,873.01 |
DisclosureSEC source: 0001209191-19-007428 · doc4.xml · nonDerivative · entry 3 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,867 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2018. F4 · price: Reflects the weighted average price of 700 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on October 1, 2018 with sale prices ranging from $74.00 to $74.29 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2018 Filed Feb 5, 2019 17:30 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 200 | $72.75 | $14,550.00 |
DisclosureSEC source: 0001209191-19-007428 · doc4.xml · nonDerivative · entry 2 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,567 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2018. F3 · price: Reflects the weighted average price of 200 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on October 1, 2018 with sale prices ranging from $72.56 to $72.94 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2018 Filed Feb 5, 2019 17:30 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 4,100 | $72.04 | $295,350.06 |
DisclosureSEC source: 0001209191-19-007428 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,767 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2018. F2 · price: Reflects the weighted average price of 4,100 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on October 1, 2018 with sale prices ranging from $71.38 to $72.35 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.